Two years after abandoning an experimental treatment for Duchenne muscular dystrophy (DMD), Santhera Pharmaceuticals AG is close to achieving its treatment goal – this time with a different molecule. The Swiss rare disease company has completed regulatory applications in both the US and Europe for its newest DMD treatment vamorolone, an anti-inflammatory drug that is being positioned as a potential alternative to corticosteroids for treating the disease.
